All Type of News
KPMA executives oppose reference price system
The minimum reference price system is expected to force many patients to give up being treated due to the high costs of original drugs, while local pharmaceutical companies have been developing a variety of generic dr...
Government to cut antihypertensive drug price
The government said it is considering reducing prices of antihypertensive drugs through price re-evaluation program, aside from the cost-effective evaluation of insurance-covered medicines.
The government will eval...
Sales of domestic 10 leading drug manufacturers take up 38.3% in ethical market
The 10 major pharmaceutical manufacturing firms in May marked the combined market share of 38.3 percent in domestic prescription medicines market, up 2.9 percent from the same month of last year.
The domestic ethic...
Can Prigrel be viable in anti-clotting market?
Sanofi Aventis’s Plavix is truly far ahead of Korea generic markers in the domestic anti-clotting market in terms of market share, however, Chong Kun Dang Pharmaceutical is hoping to challenge its competitors with its...
Ildong builds W16 bill. research centerIldong Pharm says it has invested 16.0 billion won to build its new research center at Dongtan New City of Kyunggi Province.
The Dongtan research center has about 7,670 sq. m...
|
Bioequivalence data fabrication haunts drug makers
The controversy over the bioequivalence data fabrication will flare again the Korea Medical Association plans to make public about a list of 500 medicines whose bioequivalence data were manipulated in collaboration wi...
Dong-A to withdraw margin reduction plan
Dong-A Pharm agreed to withdraw its controversial plan to reduce the wholesaler margin.
In a meeting with its associate wholesalers on June 18, Dong-A executives expressed their sincere regret over the dispute trig...
Government to toughen drug related safety regulations
The government plans to strengthen the regulations of adverse drug reaction from next month as part of its efforts to collect more cases of drug related side effects during re-examination of new drugs and postmarketin...
Green Cross to market medicine for irritable bowel syndrome, Algiron
Green Cross Corporation entered into an exclusive agreement with Boehringer Ingelheim Korea over Algiron (cimetropium bromide).
Under the agreement, GCC will market the new antimuscarinic compound in Korea on an ex...
RDA, Kwangdong sign on new drug developmentKwangdong Pharm will join the Rural Development Administration (RDA) in a development project to create new antitumor agent using corn silk (Zea mays).
The RDA signed a memor...
|
